Agentic AI streamlines oncology decisions and trial matching, cutting admin load, flagging care gaps, and widening community ...

FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...

While the survival advantage seen among Asian American women with breast cancer isn't yet ready to shape clinical practice ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting ...

FDA CBER Type C meeting will scrutinize statistical justification for pooled nonconcurrent published controls versus OST-400 ...

Hormone receptor and HER2 assessment remains the cornerstone for breast cancer subtyping and initial systemic therapy ...

Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative ...

PFS-6 reached 48.9% (95% CI, 26.3%-68.1%; P=.0047) by RANO 2.0 Kaplan-Meier estimation, exceeding the prespecified 20% standard-of-care benchmark. Survival outcomes ...

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.